Filing Details

Accession Number:
0001209191-22-015976
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-03 20:03:53
Reporting Period:
2022-01-01
Accepted Time:
2022-03-03 20:03:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1652130 Intellia Therapeutics Inc. NTLA In Vitro & In Vivo Diagnostic Substances (2835) 364785571
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1777421 Laura Sepp-Lorenzino C/O Intellia Therapeutics, Inc.
40 Erie Street; Suite 130
Cambridge MA 02139
Evp, Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-01 3,500 $0.00 5,963 No 4 M Direct
Common Stock Disposition 2022-01-01 1,148 $112.25 4,815 No 4 S Direct
Common Stock Acquisiton 2022-03-01 13,816 $0.00 18,631 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2022-01-01 3,500 $0.00 3,500 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2022-03-01 13,816 $0.00 13,816 $79.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,500 2022-01-01 2031-03-02 No 4 M Direct
13,816 2032-02-28 No 4 A Direct
Footnotes
  1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
  2. Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021.
  3. Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022.
  4. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
  5. On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
  6. This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.